17 deaths reported in Japan after drug injections

April 9, 2014

The Japanese unit of major drugmaker Janssen Pharmaceuticals says 17 people have died after being injected with its drug to treat schizophrenia since it was launched in Japan last November.

The company, an affiliate of US-based healthcare giant Johnson and Johnson, advised in Japan to use the Paliperidone Palmitate medication with great care even though it was not know whether it had caused the deaths.

The drug, brand-named Xeplion, is estimated to have been used by 10,700 people since it was released in Japan on November 19, according to a notice posted on the Japanese unit's website and seen Wednesday.

The causes of the 17 deaths included cardiac infarction, and suffocation due to inhalation of vomit.

In many cases the deaths occured about 40 days after injections of the drug.

The notice advised doctors to "fully understand that the substance remains in the body for at least four months after being injected" and to stay alert for any side-effects.

It also asked them to refrain from using the medicine with other anti-psychotic drugs because the "effectiveness and safety" of such a combined application had not been established.

The use of Xeplion has been approved in 78 countries and areas of the world as of June 2013, the has said.

Explore further: US jury hits Takeda, Eli Lilly with $9B penalty (Update)

Related Stories

US jury hits Takeda, Eli Lilly with $9B penalty (Update)

April 8, 2014
A U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and its U.S. counterpart, Eli Lilly and Co., to pay $9 billion in punitive damages over a diabetes medicine linked to cancer. The drug companies said Tuesday ...

Novartis' top Japan executives quit over cancer drug scandal (Update)

April 3, 2014
Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators.

Japan prosecutors raid Novartis over drug ad scandal

February 19, 2014
Japanese prosecutors on Wednesday raided the offices of the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, local media said.

Pfizer: Five more countries OK arthritis pill Xeljanz

July 15, 2013
Several more countries have approved Pfizer Inc.'s new rheumatoid arthritis medicine, a twice-a-day pill seen as likely to be a big moneymaker for the company.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.